Lindsey Teten, APRN
Psychiatric/Mental Health · Nebraska City, NENPI 1164838967
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 342 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 30.2% of the total.
Across 342 payments — averaging $13.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$708
- Supernus Pharmaceuticals, Inc.$543
- Harmony Biosciences LLC$240
- Takeda Pharmaceuticals U.S.A., Inc.$189
- Vanda Pharmaceuticals Inc.$188
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,714100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$113
How this compares
$4,716 in reported general payments places this provider in the 80th percentile of 255 psychiatric/mental health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HetliozTasimelteon | 13 | $351,417 |
| VraylarCariprazine Hcl | 162 | $198,053 |
| Invega SustennaPaliperidone Palmitate | 24 | $81,190 |
| Abilify MaintenaAripiprazole | 23 | $62,508 |
| RexultiBrexpiprazole | 47 | $37,334 |
| NuedextaDextromethorphan Hbr/Quinidine | 16 | $21,603 |
| QelbreeViloxazine Hcl | 24 | $16,312 |
| PristiqDesvenlafaxine Succinate | 13 | $11,163 |
| TrintellixVortioxetine Hydrobromide | 25 | $10,810 |
| Duloxetine Hcl | 146 | $4,899 |
| Ziprasidone Hcl | 46 | $4,253 |
| Quetiapine Fumarate | 231 | $3,442 |
| Clomipramine Hcl | 25 | $2,763 |
| Sertraline Hcl | 283 | $2,404 |
| Fluvoxamine Maleate | 52 | $2,302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Hetlioz | $188 | $351,41713 claims |
| AbbVieVraylar | $1,425 | $198,053162 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $708 | $99,84270 claims |
| Johnson & JohnsonInvega Sustenna | $59 | $81,19024 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $39 | $21,60316 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $543 | $16,31224 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $189 | $10,81025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Nebraska City
- Dacia OakesonHastings$32K
- Margaret Emersonla Vista$30K
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Sherry KropatschGrand Island$11K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Suzanne GreggHastings$11K
- Helen TrotterLincoln$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.